# Thymosin Alpha-1 FAQ: Straight Answers from the Research

> Thymosin Alpha-1 FAQ: direct, cited answers on side effects, safety, FDA status, dosing context, the TB-500 mix-up, and the COVID-19 and cancer data - no hype, no human dosing advice.

Direct, cited, and honest about what the evidence does and does not show.

## Who should not take thymosin alpha 1?

The literature flags theoretical cautions rather than firm prohibitions: people with active autoimmune disease (it stimulates effector immunity) [10] and solid-organ transplant recipients (it could counter intentional immunosuppression) [5] warrant caution, and pregnancy and lactation are uncharacterized [6]. None of this is settled by a trial. It is also not FDA-approved in the US [6].

## How does thymosin alpha 1 make you feel?

Honestly, most people feel nothing, and that is expected - it is an immune modulator that acts in your bloodwork, not a stimulant or sedative you sense [9]. Reported impressions skew toward fewer or shorter colds and faster recovery when run-down, which are anecdotal, not measured [9]. The most common physical note is mild injection-site redness or stinging [9].

## Is thymosin alpha 1 safe to take?

In studied, regulated use it has a benign profile: across 600,000+ patients the dominant adverse event is mild injection-site reaction, with no documented organ toxicity [9]. The real risks are theoretical cautions in autoimmunity and transplant [5][10] and, separately, the quality of unregulated research-grade material, since it is not FDA-approved in the US [6]. This is not medical advice.

## Any side effects from thymosin alpha 1 injections?

The most common is mild redness, itching, or brief stinging at the injection site, which usually settles on its own [9]. A minority report a short-lived flu-like or achy day early in a course, and a few mention a low-grade headache or tiredness [9]. Large surveillance data identifies local reactions as the dominant event with no organ toxicity at studied doses [9].

## What are the side effects of thymosin alpha 1?

Injection-site reactions (redness, itching, burning) lead the list, with occasional transient flu-like symptoms, across post-marketing surveillance of more than 600,000 treated patients and a 2024 trial review - and no documented organ toxicity at studied doses [9]. Beyond that, the cautions are theoretical (autoimmunity, transplant) [5][10] and pregnancy data is absent [6].

## What is thymosin alpha 1?

Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide first isolated from calf thymus (thymosin fraction 5); Goldstein and colleagues purified it and determined its complete sequence in 1977 [1]. In the body it is cleaved from the larger precursor prothymosin alpha [1]. The synthetic, sequence-identical drug version is called thymalfasin [4].

## What does thymosin alpha 1 do?

It modulates immunity at the innate-adaptive interface: it signals through TLR2/TLR9 on dendritic cells to mature them and matures T-cells toward a Th1 response, while also activating IDO to generate regulatory T-cells [5]. The result is dual - restoring quiet immunity while damping overactive immunity. It is not anabolic and does not build muscle [5].

## What is thymosin alpha 1 used for?

Abroad, as the generic thymalfasin, it is used mainly for chronic hepatitis B and as an immune adjuvant [4]. It has also been studied as an immunostimulatory adjuvant in cancer (melanoma, hepatocellular carcinoma, lung cancer), acting through dendritic cells and potentially mitigating checkpoint-inhibitor toxicity [7]. It is not FDA-approved for any use in the US [6].

## Is thymosin alpha 1 FDA-approved?

No. Thymosin Alpha-1 (generic name thymalfasin) is not FDA-approved for marketing in the United States; US availability is limited to investigational and compounding contexts [6]. It is approved as a drug in roughly 35 other countries [6]. The FDA also evaluated related bulk substances for compounding without endorsing them [6].

## What is TA1 peptide?

TA1 (also written Tα1) is just shorthand for Thymosin Alpha-1 - the same 28-amino-acid acetylated thymic peptide, cleaved in the body from prothymosin alpha and sold abroad in synthetic form as thymalfasin [1][4]. The various names (TA-1, Tα1, thymosin alpha 1, thymalfasin) all point to one molecule [4].

## Is TB-500 the same as thymosin alpha 1?

No - different molecule entirely. TB-500 is thymosin beta-4, a 43-amino-acid actin-binding peptide studied for tissue repair, and it is the one on the WADA prohibited list. Thymosin Alpha-1 is a 28-amino-acid immunomodulatory peptide cleaved from prothymosin alpha [1]. Different sequence, size, mechanism, and use [5].

## How long should you take thymosin alpha 1?

There is no US-approved schedule to cite. In the research, durations vary by setting: the marketed hepatitis regimen is 1.6 mg subcutaneous twice weekly (reported as study/approved-abroad data), sepsis trials ran five to seven days, and one cancer adjunct study ran weekly for up to 12 months [4][3][7]. This is research context, not a recommendation.

## How long does it take for thymosin alpha 1 to work?

The literature does not define a reliable 'time to effect' for individuals - outcomes are measured over weeks of dosing in trials, not days [6]. Pharmacokinetically the peptide itself is short-lived (elimination half-life roughly 2 hours), so any effect reflects repeated immune signaling over a course, not a single dose [12]. Many people report no perceptible effect at all [9].

## What is the dosing protocol for thymosin alpha 1?

Reported as research data only: the most-cited regimen is 1.6 mg subcutaneous twice weekly for chronic hepatitis (the thymalfasin schedule) [4]; sepsis RCTs used 1.6 mg every 12 hours for five to seven days [2][3]; the single-dose research range is 0.8-6.4 mg [6]. There is no FDA-approved US protocol and no validated self-use dose [6].

## How much thymosin alpha 1 should I take?

This site does not give human dosing. The research records doses only by population and route - for example 1.6 mg subcutaneous twice weekly in hepatitis trials and a 0.8-6.4 mg single-dose range across studies [4][6]. Because it is not an approved US drug, there is no validated dose for personal use [6]. Treat any number here as study data, not instruction.

## When is the best time to take thymosin alpha 1?

The trials do not establish an optimal time of day; they specify a route (subcutaneous) and a frequency (for example twice weekly, or every 12 hours in sepsis), not a clock time [4][3]. With an elimination half-life of roughly 2 hours, the schedule's frequency matters more than timing [12]. No timing recommendation is given here.

## Does thymosin alpha 1 help cancer?

It has been studied as an immunostimulatory adjuvant - not a standalone treatment - alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, where it may help 'turn a cold tumour hot' and reduce checkpoint-inhibitor toxicity [7]. This is a combination-protocol role in the research literature, not an approved US cancer therapy [7].

## Is thymosin alpha 1 worth it?

That is a value judgment we will not make for you, but here is the honest evidence backdrop: the strongest signal is in chronic viral hepatitis, the trial base is heterogeneous and often single-region, and the largest rigorous sepsis trial (TESTS, 1,106 adults) was null - HR 0.99, P=0.93 [3]. It is also not FDA-approved in the US [6].

## Does thymosin affect aging?

Endogenous Thymosin Alpha-1 levels decline with age, and the peptide has been studied as a vaccine adjuvant aimed at countering immunosenescence (the age-related weakening of immunity) [1][7]. But there is no controlled evidence that taking it slows aging or extends lifespan; the immune-restorative framing is mechanistic and indication-specific, not an anti-aging claim.

## Does thymosin alpha 1 reduce the mortality of severe COVID-19?

A retrospective review of 76 severe COVID-19 patients associated Thymosin Alpha-1 with lower mortality (11.11% vs 30.00%, P=0.044) and restored exhausted T-cells [6]. But that study is retrospective, and a later systematic review of about 5,300 patients found no statistically significant overall mortality benefit. The signal is encouraging and unproven, not established.

## Has anyone tried thymosin alpha 1 for chronic illness or immune issues?

Yes - it is widely discussed for immune support and post-viral fatigue, and reported impressions include fewer infections and steadier energy during recovery [9]. Those are anecdotal, not clinical evidence, and a vague 'feeling more resilient' is highly subjective [9]. Self-experimenting can also mask a treatable underlying condition that deserves real evaluation [6].

## Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?

They are different molecules. Thymosin Alpha-1 is a 28-amino-acid acetylated immunomodulatory peptide cleaved from prothymosin alpha, acting on dendritic cells and T-cells [1][5]. Thymosin beta-4 (TB-500) is a 43-amino-acid actin-binding peptide studied for tissue repair, and it - not Thymosin Alpha-1 - is on the WADA prohibited list [5].

---

The unredacted file on Thymosin Alpha-1: every study logged and cited, the null result and the not-approved status stamped in plain sight, the banned brand name blacked out on purpose - a research digest, not a clinic, a vendor, or a prescription.